7-Hydroxymitragynine vs Kratom: What's Actually Different?

You've probably seen both on the same shelf. Sometimes on the same product. Kratom and 7-hydroxymitragynine get lumped together constantly, and honestly it's not hard to see why. One comes from the other. But treating them as the same thing is a real mistake.

Kratom is a plant with centuries of use behind it. 7-OH is a concentrated or lab-made compound that's starting to show up in federal scheduling discussions and state emergency bans. The gap between them is bigger than most people realize.

Here's what's actually going on with each one, how they differ in potency and addiction risk, where the law stands heading into 2026, and why we made the call not to sell 7-OH despite how popular it's gotten.

What is kratom?

Kratom is the common name for Mitragyna speciosa, a tropical tree native to Southeast Asia. Indonesia, Malaysia, Thailand. Workers in those regions have chewed the leaves for centuries, mostly for energy and to get through long days of physical labor. In the US today it's sold mostly as a powder, capsule, or tea brewed from dried, ground leaves.

The leaves contain a lot of natural alkaloids. The two that come up most are mitragynine, which makes up about 66% of the alkaloid content in a kratom leaf, and 7-hydroxymitragynine (7-OH), which shows up naturally at less than 2% of total alkaloids.

At low doses, mitragynine acts as a mild stimulant. At higher doses, the whole-leaf profile shifts toward something more sedative and pain-relieving. Still, the whole-leaf experience is far less intense than what you get from isolated, concentrated 7-OH.

What is 7-OH?

7-OH is one of the alkaloids found in kratom, but the critical word here is isolated. Because it naturally shows up in such small amounts in the leaf, most commercial 7-OH products are either extracted and concentrated way beyond what exists in nature, or produced semi-synthetically in a lab through a process called oxidation of mitragynine.

That last part matters more than most product labels let on. A lot of what's being sold right now as "7-OH" was never actually in a kratom leaf. It was made in a lab and packaged to look like a kratom product.

Potency: the gap is not subtle

The research on this is pretty clear. In lab testing, 7-OH demonstrated pain relief about 13 times greater than morphine. Concentrated 7-OH preparations are estimated to be 30 to 40 times more potent at opioid receptors compared to whole-leaf kratom.

In practice that means you need a fraction of the dose to feel significant effects, and those effects, which include rapid-onset analgesia, euphoria, and sedation, are a lot closer to what people describe with traditional opioids than with regular kratom.

Here's how the two compare across a few key factors:

Addiction risk: this is where it really matters

This is the part most comparison articles either gloss over or bury. It's also the part with the most real-world consequences.

A 2019 study published in Addiction Biology looked at both compounds directly. Mitragynine, the primary alkaloid in whole-leaf kratom, did not show abuse potential in the tests used. More interesting: it actually reduced subsequent morphine intake in animal subjects. That's not nothing.

7-OH told a completely different story in the same study. Animals readily self-administered it. Prior exposure to it increased subsequent morphine intake. The researchers found the reinforcing effects were mediated through mu- and delta-opioid receptors. Cross-tolerance with morphine was confirmed, meaning if you're tolerant to morphine, you're already tolerant to 7-OH, and the other way around.

Poison Control Center reports for kratom-related products jumped from under 200 in 2014 to over 1,600 in 2024. About 40% of those reports came from people actively misusing the substance.

Clinically it lines up with the research. People who have used both describe 7-OH withdrawal as worse than traditional opiates. Tolerance builds in days. Physical and psychological dependence can develop fast at the concentrated doses you find in commercial products. Researchers noted in 2025 that rather than helping with opioid use disorder, which some vendors claim, 7-OH can create its own dependence and withdrawal cycle.

Side by side on the addiction and safety factors:

Where the law stands in 2025 and 2026

The legal picture for both compounds has moved fast over the last year, and it's moving in a clear direction. Regulators are drawing a hard line between natural kratom leaf and concentrated or synthetic 7-OH products.

At the federal level, neither kratom nor 7-OH is scheduled under the Controlled Substances Act as of early 2026. But that's in motion. In early 2025, the Department of Health and Human Services recommended that 7-hydroxymitragynine specifically be placed in Schedule I. The DEA is reviewing that recommendation, which typically means a public comment period before a final rule.

At the state level, the patchwork is already significant. See our kratom state laws guide for a full breakdown, but here's the current picture:

The trend is pretty unmistakable. States that are drawing distinctions are consistently protecting natural kratom while moving to ban or heavily restrict concentrated and synthetic 7-OH. Florida's AG described the ban as necessary to "avoid an imminent hazard to public safety." The FDA issued warning letters to seven companies marketing 7-OH products in June 2025 and has called it an emerging opioid threat.

How it's being sold, and why that's a problem

One of the more troubling parts of the 7-OH picture is the packaging. These aren't being sold as powerful opioid-like compounds. They're in candy-like gummies, brightly colored shots, and pills at smoke shops and gas stations, often sitting right next to kratom powder with almost no distinction made between the two.

No standardized dosing. No disclosure that the contents might have been synthesized in a lab. No warning that dependence can set in within days. The poison control data tells the story: reports shot up from under 200 in 2014 to over 1,600 in 2024, and 40% came from people actively misusing the product.

Why we don't sell 7-OH

We want to be straight about this, because it would be easy to frame it as regulatory caution. It's not.

We looked at the research. We looked at what people report about the withdrawal experience from 7-OH versus kratom. We looked at what's happening at poison control centers, in emergency rooms, and in state legislatures trying to get it off shelves. And we looked at how it's actually being marketed, like a supplement, next to vitamins, with no meaningful warning about what it actually does.

10smoke is built around giving people access to products they want without the runaround. But selling something that cross-tolerates with morphine, that animal research shows increases subsequent opioid intake, and that regulators are scrambling to schedule, and packaging it like a wellness product, is not something we're willing to do. Not because of what it does to our reputation. Because of what it could do to the people buying it.

There are plenty of effective options for stress relief, pain support, and calm focus that come with real evidence and real safety data. That's where we focus. 7-OH is not that.

Bottom line

Kratom in its natural leaf form and concentrated 7-OH are not the same product, not in potency, not in addiction risk, and increasingly not in legal status. If you're going to use either, knowing that difference isn't just academic. And if someone is selling you 7-OH as if it's just another kratom product, that's worth taking seriously.

Read our kratom legal disclaimer.

Sources

Hemby et al., Addiction Biology (2019) — abuse liability study on mitragynine and 7-hydroxymitragynine

Medscape Medical News (May 2025) — 'Legal Morphine: The Rise of Kratom and 7-OH in the US'

FDA 7-OH Warning Letters and Assessment (June/July 2025)

WUSF: Legal fight over Florida's 7-OH ban (Dec 2025)

Wikipedia: 7-Hydroxymitragynine — US Poison Control Center data

Brooks Healing Center: Kratom & 7-OH Ban By State (Jan 2026)

Pharmacy Times: Kratom Controversies (2025)

QuickMD: Kratom Ban Update 2026